New combo therapy shows promise for aggressive lung cancer
NCT ID NCT05092412
First seen May 08, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tested whether adding low-dose radiotherapy to standard chemotherapy and an immunotherapy drug (durvalumab) could help people with extensive-stage small cell lung cancer live longer without the disease getting worse. The trial enrolled 30 adults with advanced lung cancer that had spread. The goal was to see if this combination improves outcomes compared to standard treatment alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610044, China
Conditions
Explore the condition pages connected to this study.